Nab-paclitaxel + gimeracil/oteracil/tegafur in Japanese patients with HER2-negative metastatic breast cancer

Trial Profile

Nab-paclitaxel + gimeracil/oteracil/tegafur in Japanese patients with HER2-negative metastatic breast cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 30 May 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Feb 2014 New trial record
    • 14 Dec 2013 Results presented at the 36th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top